Search Results for "Kowa Lilly Activation"

13:53 EST 21st February 2017 | BioPortfolio

Matching Channels

Glucagon rDNA Lilly

Insulin Pork Lilly

Insulin rDNA Lilly

Somatropin Hgh rDNA Lilly

poly adenyl ribose polymerase PARP Inhibitors

Poly (ADP-ribose) polymerases (PARPs) are a family of nuclear enzymes implicated in the regulation of multiple physiological cellular functions, including DNA repair, gene transcription, protein modif...

Matching News

CymaBay, Kowa Pharma America Form Pact

Kowa to fully fund development through NDA of arhalofenate in the U.S.

Kowa Pharma Granted Exclusive U.S. Rights to Gout Compound

NewsKowa Pharmaceuticals America, Inc. announces agreement with CymaBay Therapeutics to license gout compound. Kowa Pharma Licenses CymaBay to Market Gout Compound

CymaBay grants Kowa U.S. rights to gout candidate

CymaBay Therapeutics Inc. (NASDAQ:CBAY) granted the Kowa Pharmaceuticals America Inc. subsidiary of Kowa Co. Ltd. (Nagoya, Japan) rights in the U.S. to arhalofenate (MBX-102), which is in development ...

Figure: Lilly's launch pad

Lilly's history lesson Lilly's launch pad During John Lechleiter's tenure as president and CEO Eli Lilly and Co. (NYSE:LLY) will have launched 10 drugs. Seven of these will be three years old or less,...

Kowa Company, Ltd. Mergers Acquisitions MA, Partnerships Alliances and Investment Report Prices from USD $350

SummaryMarketLine's Company Mergers Acquisitions MA, Partnerships Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an orga...

CymaBay licenses Kowa US rights to late-stage gout candidate

CymaBay Therapeutics Inc. licensed Kowa Pharmaceuticals America Inc. exclusive rights to develop and commercialize its Phase III-ready gout candidate arhalofenate in the US. (CymaBay retains all right...

BRIEF-Cadila Healthcare says Zydus announces settlement for Livalo tablets

* Cadila Healthcare Ltd says Zydus announces settlement with Kowa Company, Ltd., Kowa Pharmaceuticals America, Inc. and Nissan Chemical Industries, Ltd. on livalo (pitavastatin calcium) tablets

BRIEF-NanoCarrier cancels cancer medicine licensing and joint development contract with Kowa Company Ltd

* Says the co canceled the licensing for a cancer medicine NC-6300(K-912) and joint development cooperation contract with Kowa Company Ltd, which was signed on Sep. 26. 2011

Matching PubMed Articles

The Proximal Lilly Collection: Mapping, Exploring and Exploiting Feasible Chemical Space.

Venturing into the immensity of the small molecule universe to identify novel chemical structure is a much discussed objective of many methods proposed by the chemoinformatics community. To this end n...

The 9aaTAD Is Exclusive Activation Domain in Gal4.

The Gal4 protein is a well-known prototypic acidic activator that has multiple activation domains. We have previously identified a new activation domain called the nine amino acid transactivation doma...

Platinum-Catalyzed C-H Functionalization.

Recent developments in C-H bond activation and functionalization by Pt complexes are surveyed. Topics include the following: fundamental mechanistic investigations of C-H activation; stoichiometric in...

N2 activation on Al metal clusters: catalyzing role of BN-doped graphene support.

The successful sustenance of life demands an ambient abiotic process for N2 activation and dissociation. The Bosch-Haber process remains the only abiotic and synthetic means for N2 activation and its ...

Differential activation of RAW 264.7 macrophages by size-segregated crystalline silica.

Occupational exposure to crystalline silica is a well-established occupational hazard. Once in the lung, crystalline silica particles can result in the activation of alveolar macrophages (AM), potenti...

Search Whole site using Google

Quick Search
Advertisement Advertisement